The University of Southampton
University of Southampton Institutional Repository

Detection and molecular monitoring of FIP1L1-PDGFRA-positive diseases by analysis of patient-specific genomic DNA fusion junctions

Detection and molecular monitoring of FIP1L1-PDGFRA-positive diseases by analysis of patient-specific genomic DNA fusion junctions
Detection and molecular monitoring of FIP1L1-PDGFRA-positive diseases by analysis of patient-specific genomic DNA fusion junctions
To evaluate current detection methods for FIP1L1-PDGFRA in hypereosinophilic syndrome (HES), we developed a means to rapidly amplify genomic break points. We screened 202 cases and detected genomic junctions in all samples previously identified as RT-PCR positive (n=43). Genomic fusions were amplified by single step PCR in all cases whereas only 22 (51%) were single step RT-PCR positive. Importantly, FIP1L1-PDGFRA was detected in two cases that initially tested negative by RTPCR or fluorescence in situ hybridization. Absolute quantitation of the fusion by real-time PCR from genomic DNA (gDNA) using patient-specific primer/probe combinations at presentation (n=13) revealed a 40-fold variation between patients (range, 0.027-1.1 FIP1L1-PDGFRA copies/haploid genome). In follow up samples, quantitative analysis of gDNA gave 1-2 log greater sensitivity than RQ-PCR of cDNA. Minimal residual disease assessment using gDNA showed that 11 of 13 patients achieved complete molecular response to imatinib within a median of 9 months (range, 3-17) of starting treatment, with a sensitivity of detection of up to 1 in 10 5. One case relapsed with an acquired D842V mutation. We conclude that detection of FIP1L1-PDGFRA from gDNA is a useful adjunct to standard diagnostic procedures and enables more sensitive follow up of positive cases after treatment. Leukemia (2009) 23, 332-339; doi:10.1038/leu.2008.309; published online 6 November 2008 Copyright (C) 2009 Nature Publishing Group
imatinib, FIP1L1-PDGFRA, HES, MRD
0887-6924
332-339
Score, J.
ea0db6ef-c17e-4915-b216-ac67c07b26b7
Walz, C.
03a7b61b-bebd-4510-8f08-ec6b65a36809
Jovanovic, J.V.
92ddc8f4-238a-4c32-8f06-f14fb1b5f294
Jones, A.V.
daa5d0cf-4454-48c3-abb8-daf03aa21e8b
Waghorn, K.
60a6a26d-556b-41fc-84ee-dab95d63ab68
Hidalgo-Curtis, C.
b492ffa5-2adb-4901-973f-72e2432b0ee0
Lin, F.
9067ee54-a57f-4432-b390-ec81fd8aa73c
Grimwade, D.
ffb05d2d-ba42-4841-a002-3c80c3b26961
Grand, F.
26daee41-f8f8-4bae-910f-89579532ea62
Reiter, A.
8fc082eb-6b46-4412-86b2-f4c7669f0650
Cross, N.C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Score, J.
ea0db6ef-c17e-4915-b216-ac67c07b26b7
Walz, C.
03a7b61b-bebd-4510-8f08-ec6b65a36809
Jovanovic, J.V.
92ddc8f4-238a-4c32-8f06-f14fb1b5f294
Jones, A.V.
daa5d0cf-4454-48c3-abb8-daf03aa21e8b
Waghorn, K.
60a6a26d-556b-41fc-84ee-dab95d63ab68
Hidalgo-Curtis, C.
b492ffa5-2adb-4901-973f-72e2432b0ee0
Lin, F.
9067ee54-a57f-4432-b390-ec81fd8aa73c
Grimwade, D.
ffb05d2d-ba42-4841-a002-3c80c3b26961
Grand, F.
26daee41-f8f8-4bae-910f-89579532ea62
Reiter, A.
8fc082eb-6b46-4412-86b2-f4c7669f0650
Cross, N.C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4

Score, J., Walz, C., Jovanovic, J.V., Jones, A.V., Waghorn, K., Hidalgo-Curtis, C., Lin, F., Grimwade, D., Grand, F., Reiter, A. and Cross, N.C.P. (2009) Detection and molecular monitoring of FIP1L1-PDGFRA-positive diseases by analysis of patient-specific genomic DNA fusion junctions. Leukemia, 23 (2), 332-339. (doi:10.1038/leu.2008.309).

Record type: Article

Abstract

To evaluate current detection methods for FIP1L1-PDGFRA in hypereosinophilic syndrome (HES), we developed a means to rapidly amplify genomic break points. We screened 202 cases and detected genomic junctions in all samples previously identified as RT-PCR positive (n=43). Genomic fusions were amplified by single step PCR in all cases whereas only 22 (51%) were single step RT-PCR positive. Importantly, FIP1L1-PDGFRA was detected in two cases that initially tested negative by RTPCR or fluorescence in situ hybridization. Absolute quantitation of the fusion by real-time PCR from genomic DNA (gDNA) using patient-specific primer/probe combinations at presentation (n=13) revealed a 40-fold variation between patients (range, 0.027-1.1 FIP1L1-PDGFRA copies/haploid genome). In follow up samples, quantitative analysis of gDNA gave 1-2 log greater sensitivity than RQ-PCR of cDNA. Minimal residual disease assessment using gDNA showed that 11 of 13 patients achieved complete molecular response to imatinib within a median of 9 months (range, 3-17) of starting treatment, with a sensitivity of detection of up to 1 in 10 5. One case relapsed with an acquired D842V mutation. We conclude that detection of FIP1L1-PDGFRA from gDNA is a useful adjunct to standard diagnostic procedures and enables more sensitive follow up of positive cases after treatment. Leukemia (2009) 23, 332-339; doi:10.1038/leu.2008.309; published online 6 November 2008 Copyright (C) 2009 Nature Publishing Group

This record has no associated files available for download.

More information

Published date: February 2009
Keywords: imatinib, FIP1L1-PDGFRA, HES, MRD

Identifiers

Local EPrints ID: 69894
URI: http://eprints.soton.ac.uk/id/eprint/69894
ISSN: 0887-6924
PURE UUID: 14848753-3dbd-4a6d-b45c-d682635b331c
ORCID for N.C.P. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 09 Dec 2009
Last modified: 14 Mar 2024 02:46

Export record

Altmetrics

Contributors

Author: J. Score
Author: C. Walz
Author: J.V. Jovanovic
Author: A.V. Jones
Author: K. Waghorn
Author: C. Hidalgo-Curtis
Author: F. Lin
Author: D. Grimwade
Author: F. Grand
Author: A. Reiter
Author: N.C.P. Cross ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×